Gujarat Themis Biosyn Ltd

₹ 738 1.49%
02 Feb 2:35 p.m.
About

Gujarat Themis Biosyn is principally engaged in the business pertaining to manufacturing of pharmaceuticals and medicinal chemicals.

Key Points

Pioneer in manufacturing Rifampicin
The Company entered into Technical & Financial collaboration with Yuhan Corporation, South Korea. With Yuhan’s know-how, GTBL became India’s first Company to start commercial production of Anti-tuberculosis drug Rifampicin. [1]

  • Market Cap 1,072 Cr.
  • Current Price 738
  • High / Low 921 / 317
  • Stock P/E 20.1
  • Book Value 92.2
  • Dividend Yield 0.84 %
  • ROCE 66.8 %
  • ROE 50.4 %
  • Face Value 5.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 58.4% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 56.0%

Cons

  • Stock is trading at 7.87 times its book value
  • Working capital days have increased from 98.3 days to 158 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
16 31 26 16 27 24 23 32 35 19 29 45 48
15 16 13 9 12 14 15 16 17 9 16 22 23
Operating Profit 2 15 13 7 15 11 8 17 18 10 13 23 24
OPM % 12% 49% 50% 42% 54% 44% 36% 52% 53% 53% 45% 51% 51%
1 0 0 1 1 1 1 1 1 1 2 1 1
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 1 1 1 1 1 1 1
Profit before tax 2 14 13 7 15 11 8 17 18 10 14 24 25
Tax % 19% 33% 15% 19% 25% 31% 29% 25% 25% 26% 29% 25% 26%
Net Profit 2 10 11 6 11 7 6 13 14 7 10 18 19
EPS in Rs 1.10 6.68 7.54 3.83 7.81 5.14 3.99 8.89 9.49 4.90 6.74 12.23 12.87
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
14 9 28 30 31 33 36 39 41 85 91 115 140
15 11 25 24 25 27 30 33 34 53 50 57 70
Operating Profit -1 -2 3 6 7 6 6 6 7 32 40 58 70
OPM % -8% -26% 11% 21% 21% 19% 17% 16% 18% 37% 45% 51% 50%
0 6 0 0 -0 0 0 0 2 2 3 4 5
Interest 1 1 1 1 0 0 0 0 0 1 1 1 1
Depreciation 1 1 1 1 1 1 1 1 1 1 2 2 2
Profit before tax -3 2 1 5 5 5 5 5 8 31 41 59 72
Tax % 0% 0% 0% 0% 0% 0% 10% 20% 22% 24% 26% 26%
Net Profit -3 2 1 5 5 5 4 4 6 24 30 44 53
EPS in Rs -2.83 1.37 0.74 3.12 3.16 3.19 3.01 2.66 4.41 16.29 20.77 30.02 36.74
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 10% 0% 37%
Compounded Sales Growth
10 Years: 29%
5 Years: 26%
3 Years: 41%
TTM: 22%
Compounded Profit Growth
10 Years: 28%
5 Years: 58%
3 Years: 90%
TTM: 34%
Stock Price CAGR
10 Years: 53%
5 Years: 72%
3 Years: 135%
1 Year: 68%
Return on Equity
10 Years: %
5 Years: 54%
3 Years: 56%
Last Year: 50%

Balance Sheet

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
12 12 7 7 7 7 7 7 7 7 7 7 7
Reserves -27 -25 -17 -13 -8 -3 1 5 11 35 63 96 127
14 11 11 9 6 3 4 1 6 8 5 1 1
14 20 17 13 9 8 9 8 8 14 14 18 25
Total Liabilities 13 17 18 16 15 15 21 20 33 64 88 122 161
9 11 12 11 10 9 11 11 15 17 19 19 19
CWIP 0 1 0 0 0 0 0 0 1 0 2 13 23
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
4 6 6 5 5 5 11 10 17 47 67 90 119
Total Assets 13 17 18 16 15 15 21 20 33 64 88 122 161

Cash Flows

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
3 2 0 4 3 4 3 6 1 1 11 40
-1 -4 -3 -0 -0 -1 -3 -1 -6 -3 -2 -30
-2 2 2 -3 -3 -3 -0 -4 5 2 -5 -14
Net Cash Flow 0 0 -0 1 -1 -0 0 1 0 -0 3 -4

Ratios

Figures in Rs. Crores

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 0 109 37 15 28 24 71 26 52 87 59 80
Inventory Days 88 58 78 194 144 255
Days Payable 737 1,498 947 240 84 145
Cash Conversion Cycle 0 -540 -1,403 15 28 24 71 -844 52 41 119 189
Working Capital Days -510 -681 -172 -128 -76 -69 -30 -43 -58 42 96 158
ROCE % -2,147% 208% 121% 81% 55% 42% 45% 84% 67% 67%

Shareholding Pattern

Numbers in percentages

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
74.99 74.99 74.99 74.99 74.99 74.99 74.99 74.99 74.99 74.99 75.00 75.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.31 0.31 0.31 0.03 0.03
24.97 24.97 24.97 24.97 24.97 24.97 24.97 24.70 24.70 24.69 24.98 24.96

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents